Skip to main content
POM logo

Pomdoctor Limited (POM) Stock Price & Analysis

Pomdoctor Limited (POM) — MoonshotScore 21/100 (Weak band), calculated Nov 18, 2026. Price $1.61 (0.00%), as of the Nov 19, 2026 trading session; market cap $57.9M.

Educational signal · not a buy or sell recommendation · How to read this

$1.61 $0.00 (0.00%) Market Cap $57.9M

Pomdoctor Limited · POM · NASDAQ

The company connects patients to doctors and pharmaceutical products through its internet hospital and pharmaceutical supply chain platform.

Price as of Nov 19, 2026

Key Statistics

21 of 100

MoonshotScore v2 · Pomdoctor (POM)

Weak
Business Quality Average (40)
Financial Safety Fragile (4)
Valuation Bubble (11)
Growth Durability Shrinking (5)
Momentum Falling (17)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

A fragile balance sheet, stalling growth and an expensive valuation, though quality is only middling, and the price trend has turned against it. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Average; Financial Safety: Fragile; Valuation: Bubble; Growth Durability: Shrinking; Momentum: Falling.

  • quarterly revenue CN¥27M (Q2 FY2026, quarter ended Jun 30, 2026)

Holding back: balance-sheet strain, a rich price, soft growth, weak price trend

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for POM (52 recorded, newest six shown)
RecordedScoreBand
20Weak
20Weak
21Weak
21Weak
21Weak
21Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$1.61
Change on the day0.00%
Market capitalisation$57.9M—
Shares traded on the day34.1K

Price & events

Other perspectives

Council score for Pomdoctor (POM): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Neutral
Financial Safety Negative
Valuation Negative
Growth Durability Negative
Momentum Negative

Legends Council

3 lenses, 3 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation

Financial Health Weak
Margin of Safety Fairly Valued
Profit Margin Weak
Debt/Equity Strong
ROE Moderate
Gross Margin Weak

Read on: Nov 19, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

One of these lenses reads this company more favourably than the MoonshotScore does: Englander-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

The Munger lens reads the current price as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Pomdoctor (POM), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Pomdoctor Limited (POM) is listed on NASDAQ. It employs 165 people. In Q2 FY2026 it reported revenue of CN¥27M and net income of -CN¥34M. The market values it at $57.9M.

2 · Latest results

What do the latest results show for Pomdoctor (POM)?

Short answer · as of

The most recent reported quarter, Q2 FY2026, carried revenue of CN¥27M.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q2 FY2026CN¥27M-CN¥34M-CN¥14.87 (diluted)
Q1 FY2026CN¥93M-CN¥115M-CN¥14.87 (diluted)
Q4 FY2025CN¥113M-CN¥70M-CN¥16.12 (diluted)
Q3 FY2025CN¥113M-CN¥70M-CN¥16.12 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Pomdoctor (POM)?

Short answer

What is holding it back is balance-sheet strain, a rich price, soft growth, weak price trend. The distress and quality screens read Piotroski F 3. Trailing ratios: current ratio 0.35.

5 · Peer comparison

How does Pomdoctor compare with its peers?

Short answer

Pomdoctor's score ranks 2nd of 2 in the bounded comparison shown, against 1 same-model peer. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Erasca, Inc. (ERAS) Named competitor$14.22 Nov 19, 2026$4.99B67 5-pillar Nov 18, 2026
Pomdoctor (POM) — this page$1.61$57.9M21

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held POM in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported POM in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Pomdoctor (POM)?

Read these with our analysis →

Common Questions About POM

These answers are editorial: 1 of these 9 answers is drawn from the POM research dossier (written May 10, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for POM?

POM carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Is POM a good stock to buy?

Stock Expert AI does not rate POM buy, sell or hold. Pomdoctor Limited carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the POM stock price today?

The last price recorded for Pomdoctor Limited (POM), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What do analysts say about POM stock?

Analyst coverage of Pomdoctor Limited (POM) is limited due to its small market capitalization and relatively recent entry into the public markets.

What are the key factors to evaluate for POM?

Pomdoctor Limited (POM) holds a MoonshotScore in the low range. This strategy can improve patient trust and expand the company's service offerings. Not financial advice.

How frequently does POM data refresh on this page?

POM's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven POM's recent stock price performance?

Pomdoctor Limited (POM) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Online platform for pharmaceutical sales and chronic disease management. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider POM overvalued or undervalued right now?

Pomdoctor Limited (POM) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Can I buy fractional shares of POM?

Fractional-share availability for Pomdoctor Limited (POM) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 12 figures on this page — 8 from Financial Modeling Prep (FMP), 3 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.